Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV: ATE) is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.
ATB-346 targets the global need for a GI-safe anti-inflammatory painkiller, a growing market that currently generates annual sales of over $12 billion. Said Chief Scientific Officer Dr. John Wallace, "We are delighted that the planned pre-clinical studies have been finished, and that these studies confirm and expand upon the extensive academic work already conducted on ATB-346. We are grateful to our partners and service providers for their assistance, which has enabled us to conduct these studies on schedule."
CEO Dan Legault added, "It is a significant milestone for Antibe to have completed its planned pre-clinical work on ATB-346. We look forward to sharing additional progress with Antibe's stakeholders as we proceed with an application to Health Canada for permission to initiate the first human trials later this year."
Liraglutide activates key brain circuits to trigger weight loss in obesity